.png)
Drug 1 Disrupts COVID- 19 virus growth by reducing the effectiveness of copper transporters within the cells.
Drug 2 Accelerates Coronavirus antibody formation.
Combined, inhibit Virus Entry into the Cells and Inhibit Virus replication.
Drug 1 Stops the virus from creating lung damage and heart failure as it is an antioxidant and inhibitor of the VEGF production that inhibits the virus’s intravascular inflammatory and procoagulant mechanisms.
Drug 1 Inhibits the virus-induced activity of the important hypoxia-induced transcription factors HIF-1alpha and HIF-2 alpha. (Bridges Hypoxia and inflammation)
Combined the drugs Inhibit TNF alpha and nitric oxide production
Combined they block cytokines that play an important part in the manifestation of the inflammatory response, including IL-1, IL-6, IL-8, RP, bradykinin receptor, activation of 5-Lo and COX1.
Drug 1 Inhibits Cell-to-Cell interactions within the vessel, blocking the virus progression.
Combined, they block the virus from creating chemotaxis of inflammatory cells into the injured lung and the heart.
Drug 2 Blocks the Virus from causing leukotriene B4 production that activates the chemotaxis of neutrophils and macrophages into the injured lung and also causes endothelial cell damage.
Combined they Decrease Virus’s ability to trigger the master inflammatory mediator transcription factor NFkappaB activation, protecting endothelial cells from damage.
Drug 2 Prevents the Virus from activating chemotaxis and addresses LTB4, and in addition to the synthesis of LTC4, addressing peptido-leukotrienes that are vaso-and bronchospastic.